Editas Medicine. has filed a patent for engineered nucleic acids encoding genome editing system components and RNA-guided nucleases with inserts recognized by guide RNAs. The claim details have been canceled. GlobalData’s report on Editas Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Editas Medicine Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Editas Medicine, CRISPR genome editing was a key innovation area identified from patents. Editas Medicine's grant share as of January 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.

Genome editing system components using engineered nucleic acids

Source: United States Patent and Trademark Office (USPTO). Credit: Editas Medicine Inc

A patent application (Publication Number: US20230416787A1) has been filed for a nucleic acid molecule that encodes a Cpf1 protein, with specific characteristics outlined in the claims. The molecule includes a eukaryotic nucleic acid sequence that is at least 17 nucleotides long and contains or is adjacent to a protospacer adjacent motif (PAM) recognized by the Cpf1 protein. Additionally, the molecule may also include a guide RNA (gRNA) with a targeting domain complementary to a portion of the eukaryotic nucleic acid sequence near the PAM.

Furthermore, the patent application describes a transiently-active genome editing system utilizing the Cpf1 protein encoded by the nucleic acid molecule. This system is designed to alter both a cellular endogenous target gene and the expression of the Cpf1 protein itself. The method involves delivering a Cpf1/gRNA complex to the cell, which can cleave the nucleic acid encoding the engineered Cpf1 protein and the target site in the cell. The engineered Cpf1 protein in this system may have specific amino acid insertions or substitutions, maintaining high nuclease activity and sequence identity to known Cpf1 proteins. Overall, the patent application outlines a comprehensive approach to genome editing using Cpf1 proteins and associated nucleic acid molecules, potentially opening up new avenues for precise genetic modifications.

To know more about GlobalData’s detailed insights on Editas Medicine, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies